Quantcast

Latest Prostate cancer Stories

2014-09-17 20:22:13

Oral presentation at American Society for Radiation Oncology Annual Meeting describes Decipher's ability to identify high-risk prostate cancer patients that may benefit from radiation therapy after surgery, improving treatment decision-making SAN FRANCISCO, Sept. 17, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that data featured in an oral presentation at the 56(th) Annual Meeting of the American Society for Radiation Oncology (ASTRO) demonstrates convincing evidence of the...

2014-09-17 12:28:04

The Crusade for Greater Prostate Imaging Awareness in Men with Prostate Cancer MARINA DEL REY, Calif., Sept. 17, 2014 /PRNewswire/ -- Prostate Oncology Specialists announces the launch of the Prostate Vanguard, an awareness campaign to educate men about new imaging technology destined to replace multiple rectal needle biopsies of the prostate. Annually, a million men undergo random needle biopsy of the prostate gland through the rectum. Multi-parametric MRI (MP-MRI) of the prostate...

2014-09-17 12:27:36

WASHINGTON, Sept. 17, 2014 /PRNewswire-USNewswire/ -- ZERO - The End of Prostate Cancer appointed former Department of Defense Prostate Cancer Research Program (PCRP) Director Leo Giambarresi, Ph.D., to its Board of Directors. Additionally, past CEO Quentin "Skip" Lockwood will assume the role of Vice Chairman of the Board while ESPN Commentator and former Vice Chairman Mitch Laurance will remain on the organization's board. http://photos.prnewswire.com/prnvar/20130129/DC50244LOGO...

2014-09-17 12:26:49

OMAHA, Neb., Sept. 17, 2014 /PRNewswire/ -- ScanMed of Resonance Innovations LLC is proud to introduce a world's first to the MRI market: The PROCURE(TM) Coil! http://photos.prnewswire.com/prnvar/20140916/146548 The latest product in ScanMed's Game-Changer Coil Line is the The PROCURE(TM) Coil (Prostate, Rectum, Ovaries, Cervix, Uterus, Reproductive). The PROCURE(TM) features a first-of-a-kind, lightweight SemiFlex(TM) design that facilitates effortless and accurate positioning....

2014-09-17 08:30:32

Proprietary genomic-based VPAC1 cancer biomarker to be co-developed worldwide? PARK CITY, Utah, Sept. 17, 2014 /PRNewswire/ -- NuView Life Sciences, Inc. (NuView) announced entry into an exclusive global licensing and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to further develop and commercialize NuView's investigative genomic-based diagnostic biomarker to detect cancers of the breast and prostate. The agreement also includes all other future...

2014-09-17 00:20:34

Article in Baltimore Sun WASHINGTON, Sept. 16, 2014 /PRNewswire-USNewswire/ -- George Washington University cancer researcher Dr. Patricia Berg, former White House Drug Policy Spokesman and House Aging Committee Director Robert Weiner, and Solutions for Change Senior Policy Analyst Tom Sherman, are asserting that Federal cancer research funding cuts are threatening the nation's mortality rate. The trio wrote an article, "FUND CANCER RESEARCH TO KEEP BREAKTHROUGHS COMING," which...

2014-09-16 16:29:14

LONDON, Sept. 16, 2014 /PRNewswire/ -- This report analyzes the worldwide markets for Brachytherapy in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles...

2014-09-16 08:29:16

BOTHELL, Wash. and VANCOUVER, B.C., Sept.16, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the Phase 3 AFFINITY trial. The international, randomized, open-label Phase 3 AFFINITY trial is designed to evaluate the potential of custirsen to improve survival outcomes in approximately 630 men with metastatic castrate-resistant prostate cancer (CRPC). Patients have been randomized to receive second-line...

2014-09-16 04:21:18

WHIPPANY, N.J., Sept. 16, 2014 /PRNewswire/ -- Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer who have rising Prostate Specific Antigen (PSA) levels and no detectable metastases. The trial is designed to...

2014-09-15 23:04:47

A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment. Pittsburgh, Pennsylvania (PRWEB) September 15, 2014 A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment. The analysis, published today in the American Journal of Pathology,...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related